Current Takeaway
Mitochondrial and metabolic dysfunction remain one of the strongest biological frameworks for understanding exertional intolerance in ME/CFS and related post-COVID illness. The picture is becoming more coherent across tissues: newer studies now connect metabolomic abnormalities, objective muscle dysfunction, and direct in vivo evidence of impaired brain energy buffering rather than relying on a single blood marker or one isolated pathway.
The latest additions strengthen that pattern without resolving it. New conference and preprint data point to sex-specific arginine and polyamine abnormalities, intrinsic metabolic reprogramming in patient-derived myogenic cells, large-cohort dried blood spot signatures converging on carnitine shuttle and TCA-cycle pathways, persistent handgrip-based muscle dysfunction, and reduced cerebral ATP-to-phosphocreatine ratios in a post-COVID cohort that partly overlaps with ME/CFS criteria. Together these findings support a distributed energy-processing problem rather than a universal one-size-fits-all signature.
Important uncertainty remains. Several of the newest signals come from conference talks, preprints, or exploratory models, and some cohorts are small, female-only, or based on self-reported PEM-like phenotypes rather than clinically adjudicated ME/CFS. A recent Long COVID metabolic review remains useful as synthesis support, but it does not add new primary human evidence on its own.
Why This Matters
Elucidating the molecular pathways of mitochondrial and metabolic failure provides a physical, measurable basis for the profound weakness and post-exertional malaise reported by patients. By shifting the clinical explanation from subjective fatigue to specific enzymatic defects (such as Complex V or respiratory supercomplex disruption), research identifies concrete biological targets for drug repurposing and therapeutic development. Furthermore, tracing these cellular energy blocks explains the failure of standard aerobic training protocols, which can exacerbate the intracellular ion imbalances and mitochondrial damage seen in skeletal muscle. Understanding the interactions between immune mediators (like sIL2R), vascular perfusion defects, and mitochondrial respiration guides the development of multi-system treatment strategies, such as combining vasoactive agents with mitochondrial cofactors and cellular stress inhibitors.
State of Evidence
- Established: ME/CFS and Long COVID cohorts repeatedly show abnormalities in energy metabolism, including post-exertional recovery failure, altered lipid and amino-acid handling, and objective peripheral muscle dysfunction. Structural and functional muscle findings continue to support impaired energy handling rather than simple deconditioning.
- Plausible but early: Newer 2026 studies suggest that the signal is heterogeneous and tissue-specific. Male ME/CFS cohorts may show arginine-NO pathway imbalance, patient-derived myogenic cells may shift toward branched-chain amino acid degradation, dried blood spot metabolomics may recover pathway-level convergence at scale, and phosphorus-MRS may detect impaired cerebral high-energy phosphate buffering.
- Not established: No single mitochondrial or metabolomic signature has been shown to define all patients, separate ME/CFS cleanly from overlapping post-viral syndromes, or prove one causal entry point. Drug-repurposing outputs derived from transcriptomic datasets remain hypothesis-generating rather than treatment evidence.
- Key limitations: Several recent additions are conference presentations or preprints without full peer-reviewed methods. Some cohorts are small, sex-restricted, or based on self-reported phenotypes. Narrative reviews, including the 2026 Long COVID metabolic synthesis, are helpful for context but do not replace primary cohort data.
Timeline
2019-07-04 - Exertion linked to systemic hypermetabolism and purine depletion
- What changed: A clinical metabolomic analysis of blood and urine from 46 patients and 26 controls identified that the severity of post-exertional malaise is associated with a hypermetabolic state characterized by increased urinary excretion of methylhistidine, mannitol, and acetate, alongside a significant drop in serum hypoxanthine.
- Why it matters: This establishes a concrete biological connection between physical exertion and systemic metabolic crashes, pointing to muscle protein breakdown, gut barrier dysfunction, and hypoacetylation as key drivers of patient-reported symptoms.
- What it does not prove yet: The study’s cross-sectional design cannot prove that these metabolomic alterations cause the post-exertional crash rather than being secondary markers, and the findings require validation in larger, multi-center cohorts to control for recall bias.
Sources:
2020-02-06 - Isolated mitochondrial Complex V inefficiency identified in immune cells
- What changed: An in vitro study of immortalized lymphocytes (lymphoblasts) from 51 patients and 22 controls discovered an isolated efficiency defect in Complex V (ATP synthase), which was accompanied by compensatory upregulation of Complexes I, II, and IV and increased fatty acid usage.
- Why it matters: This shifts the focus from generalized mitochondrial failure to a specific enzymatic bottleneck, demonstrating that cells compensate to maintain ATP at rest but remain chronically stressed, leaving them unable to handle acute energy demands.
- What it does not prove yet: The study does not establish whether this Complex V inefficiency is due to a direct genetic mutation or regulatory dysfunction, nor does it confirm if this defect is present in primary skeletal muscle tissue in vivo.
Sources:
2022-03-31 - Longitudinal plasma metabolomics reveals post-exercise recovery failure
- What changed: A study tracking 1,157 plasma metabolites before and after two 24-hour-separated cardiopulmonary exercise tests (CPETs) in 60 patients and 45 controls showed that metabolic differences and disruptions in lipid and glutamate pathways peaked during the 24-hour recovery period.
- Why it matters: This provides objective biological evidence for recovery failure following exertion, demonstrating that dynamic physical stress testing reveals metabolic pathology that remains hidden in a resting state.
- What it does not prove yet: Many of the most significantly altered metabolites remain chemically unidentified, and the small size of the male cohort limits statistical power for drawing firm sex-specific conclusions.
Sources:
2022-12-09 - Muscle sodium overload confirmed post-exercise via sodium-MRI
- What changed: A pilot study utilizing specialized -magnetic resonance imaging in 6 female patients and 6 controls showed significantly elevated muscle tissue sodium content at rest and an exaggerated sodium increase with delayed clearance after brief exercise, correlating with reduced handgrip strength.
- Why it matters: This supports the hypothesis of muscle sodium overload, suggesting that tissue hypoperfusion and cellular energy deficits impair membrane ion pumps, leading to muscle weakness, fatigue, and pain.
- What it does not prove yet: The small pilot sample size limits generalizability, and the MRI protocol was unable to distinguish between extracellular and intracellular sodium accumulation.
Sources:
2023-08-14 - Endoplasmic reticulum stress protein WASF3 disrupts mitochondrial respiration
- What changed: A mechanistic study using patient skeletal muscle biopsies, transgenic mice, and cell lines demonstrated that endoplasmic reticulum (ER) stress induces the protein WASF3, which physically interferes with the assembly of mitochondrial Complex III and IV supercomplexes.
- Why it matters: This identifies a specific molecular pathway (“ER stress response failure”) driving exercise intolerance and muscle energy failure, and demonstrates that reducing ER stress with chemical chaperones can restore normal mitochondrial respiration in vitro.
- What it does not prove yet: The upstream trigger that initiates the chronic ER stress response in ME/CFS patients remains unknown, and the safety and clinical efficacy of ER stress inhibitors like Salubrinal or TUDCA have not been tested in human trials.
Sources:
2024-10-13 - Soluble IL-2R linked to muscle mitochondrial dysfunction in post-COVID fatigue
- What changed: A prospective study of 11 patients and 17 controls showed that the circulating inflammatory cytokine soluble IL-2 receptor (sIL2R) is highly elevated in post-COVID fatigue and directly impairs Complex I mitochondrial respiration in cultured muscle cells.
- Why it matters: This establishes a direct immunometabolic link showing how systemic T-cell activation can cross over to cause muscle tissue energy failure, identifying sIL2R as a potential biomarker and therapeutic target.
- What it does not prove yet: The clinical efficacy of neutralizing sIL2R remains untested, and the direct pathobiological mechanism needs validation in primary human muscle cells rather than mouse cell models.
Sources:
2024-11-06 - Consolidating model of acquired ischemic mitochondrial myopathy in skeletal muscle
- What changed: A systematic review consolidated experimental data to propose that ME/CFS and Long COVID present as an “acquired ischemic mitochondrial myopathy,” where impaired blood flow triggers a self-sustaining cycle of sodium-calcium overload, mitochondrial damage, and tissue necrosis.
- Why it matters: This integrates vascular hypoperfusion and cellular bioenergetics into a unified clinical model, shifting focus from persistent viral replication to local muscle tissue restoration and perfusion-enhancing therapies like pyridostigmine or vericiguat.
- What it does not prove yet: The proposed model is a theoretical synthesis of separate studies and requires validation through longitudinal cohort studies tracking the progression from vascular hypoperfusion to muscle tissue necrosis in vivo.
Sources:
2025-08-06 - Impaired autophagy protein ATG13 triggers macrophage-driven muscle nerve damage
- What changed: A preclinical study using a transgenic mouse model () showed that reducing the autophagy protein ATG13 causes mitochondrial dysfunction, shifting macrophages to a pro-inflammatory M1 state that infiltrates muscle vessels and damages nerve myelin sheaths.
- Why it matters: This links cellular “housekeeping” defects (autophagy) directly to neuroinflammation, demyelination, and post-exertional muscle weakness, providing a mechanistic rationale for evaluating autophagy-promoting agents like rapamycin.
- What it does not prove yet: The genetic knockout model in mice may not capture the heterogeneous, non-congenital causes of autophagy dysfunction in human ME/CFS patients.
Sources:
2025-09-09 - Autoantibodies against mitochondrial proteins predict post-COVID disability
- What changed: A cohort analysis of 45 patients and 30 controls identified that IgG autoantibodies against mitochondrial proteins (AIFM1, SURF1) and neuronal proteins (DAB1) are significantly elevated in Post-COVID Syndrome and predict lower functional status and respiratory symptoms.
- Why it matters: This supports an autoimmune driver of energy failure, suggesting that antibodies directly attack the enzymes responsible for mitochondrial respiration and brainstem respiratory control.
- What it does not prove yet: The study does not prove that these autoantibodies are the direct cause of the symptoms rather than a secondary biomarker, and replication in larger sex-stratified cohorts is required.
Sources:
2025-09-12 - Soluble SMPDL3B levels define subclinical kidney stress and metabolic subtypes
- What changed: A metabolomic study of 56 patients and 16 controls showed that reduced urine-to-plasma ratios of SMPDL3B predict early-stage subclinical renal stress and correlate with systemic mitochondrial metabolite depletion (such as succinic acid).
- Why it matters: This highlights subclinical renal podocyte stress as a feature of the systemic energy deficit, and shows that patients can be stratified into three distinct metabolic and lipid endophenotypes to enable personalized diagnostics.
- What it does not prove yet: The cross-sectional design cannot establish causality, and these subclinical kidney alterations have not been confirmed via direct tissue biopsy validation.
Sources:
2025-11-07 - Integrated genomic and epigenomic analysis maps mitochondrial susceptibility
- What changed: A molecular review synthesized twin studies, Candidate Gene Association studies, and the DecodeME GWAS to map the role of mitochondrial DNA variations and epigenetic changes in predisposing individuals to post-viral chronic illness.
- Why it matters: This establishes that genetic variations in energy metabolism pathways and environmental-induced epigenetic shifts combine to drive mitochondrial dysfunction and transposable element activation.
- What it does not prove yet: The review consolidates existing data and does not provide new primary clinical datasets, and the identified genomic/epigenomic associations require replication across diverse multi-ethnic populations.
Sources:
2025-12-16 - Coordinated multi-system map links immune cell energy stress to vascular dysfunction
- What changed: A multi-omics study of 61 patients and 61 controls identified severe cellular energy stress (low ATP/ADP ratio, elevated AMP/ADP) in immune cells, coexisting with immature immune cell profiles and vascular endothelial dysfunction.
- Why it matters: This provides a unified biological map showing that metabolic, immune, and vascular systems fail in tandem, and identifies a 7-marker diagnostic signature that predicts ME/CFS with high accuracy.
- What it does not prove yet: The 7-variable model requires validation in independent, external patient cohorts, and the study cannot determine which system’s dysfunction initiates the multi-system collapse.
Sources:
2026-01-01 - Systematic review details persistent metabolomic and endocrine signatures in Long COVID
- What changed: A systematic review of clinical and omics literature consolidated evidence of persistent metabolic and endocrine dysfunction in Long COVID, including low morning cortisol, reduced free T3, and depleted ATP production 12 months post-infection.
- Why it matters: This confirms that post-viral fatigue syndromes are marked by objective, long-term disruptions in endocrine regulation and mitochondrial respiration, reinforcing the biological similarities between Long COVID and ME/CFS.
- What it does not prove yet: The high clinical heterogeneity among symptom clusters makes it challenging to establish a single universal biomarker, and the efficacy of hormonal or metabolic treatments remains unproven in clinical trials.
Sources:
2026-01-08 - Lipid accumulation and membrane fluidity disruption identified in patient cell lines
- What changed: A multi-omics case-control study of 15 patients and 17 controls showed significant accumulation of triglycerides and free fatty acids, a shift toward saturated lipid content, and a reduction in the lipid PC(O-38:4) in patient cell lines.
- Why it matters: This demonstrates cellular lipid dysregulation and hyperactivation of the PTDSS1 enzyme, which may disrupt lipid rafts and cell membrane fluidity, potentially impairing immune receptor signaling in B cells.
- What it does not prove yet: The study utilized immortalized lymphoblastoid cell lines rather than primary human immune cells, and the findings need validation in primary cells while controlling for body mass index (BMI).
Sources:
2026-01-27 - Humidifier disinfectant exposure linked to mitochondrial and neural pathology
- What changed: A dual human and animal study showed that exposure to polyhexamethyleneguanidine phosphate (PHMG-p) triggers significant mitochondrial swelling, disrupted cristae, and reduced oxidative phosphorylation, alongside hypothalamic neuroglial activation and BBB disruption.
- Why it matters: This establishes that toxic environmental exposure can act as a direct trigger for the mitochondrial and neuroinflammatory changes characteristic of ME/CFS.
- What it does not prove yet: The mouse model’s intratracheal administration route may not mirror the diverse routes of human toxic exposures, and the clinical efficacy of mitochondrial stabilization in exposed patients remains unproven.
Sources:
2026-02-03 - Large replication study challenges presence of circulating mitochondrial-inhibiting factors
- What changed: A pre-registered study of 67 patients and 53 controls performed over 1,700 mitochondrial stress tests on healthy myoblasts, finding no significant difference in mitochondrial respiration after exposing them to patient versus control serum.
- Why it matters: This directly challenges the hypothesis that universal circulating blood factors are the primary cause of muscle cell mitochondrial impairment in patients, narrowing down the search to localized or tissue-specific intracellular mechanisms.
- What it does not prove yet: The study does not rule out localized, transient, or patient-specific intracellular drivers, nor does it address whether immune complexes require specific host-cell receptors absent in healthy myoblasts.
Sources:
2026-02-19 - Database re-analysis confirms multi-tissue mitochondrial gene expression changes
- What changed: A systematic re-analysis of bulk, single-cell, and proteomic datasets from mapMECFS and DecodeME GWAS identified consistent downregulation of mitochondrial genes MT-RNR1 and MT-RNR2, mapping 201 FDA-approved compounds for drug repurposing.
- Why it matters: This standardizes diverse datasets to confirm mitochondrial dysregulation as a core multi-tissue signature and identifies repurposed therapeutic leads (such as thiamine, dimethyl fumarate, and ruxolitinib).
- What it does not prove yet: The consistency of individual gene expression across studies remains low due to small sample sizes, and the clinical efficacy of the identified drug candidates must be evaluated in prospective trials.
Sources:
2026-03-16 - Purinergic signaling defects proposed to link taste dysfunction and systemic fatigue
- What changed: A perspective study proposed a pathological model where defects in ATP release from Type II taste receptor cells and impaired signaling through purinergic receptors (P2X2/P2X3) link dysgeusia (taste dysfunction) to chronic fatigue.
- Why it matters: This suggests that chemosensory dysfunction acts as a direct indicator of systemic purinergic energy failure, proposing taste testing as a simple, non-invasive clinical screening tool for disease progression.
- What it does not prove yet: Chemosensory symptoms can be confounded by multiple clinical factors, and the purinergic pathway’s causal role requires direct verification in clinical cohorts.
Sources:
2026-04-02 - SARS-CoV-2 envelope protein disrupts mitochondrial cardiolipin and TCA cycle
- What changed: An in vitro study demonstrated that the SARS-CoV-2 envelope (E) protein localizes to host cell mitochondria, causing significant cardiolipin depletion, electron transport chain disruption, and a shift toward aerobic glycolysis.
- Why it matters: This outlines a direct molecular mechanism of viral-mediated mitochondrial hijacking, explaining how viral components drive persistent host metabolic stress and reactive oxygen species retention.
- What it does not prove yet: The study was performed in vitro, and whether persistent E protein presence occurs and drives chronic symptoms in patients with Long COVID in vivo remains unproven.
Sources:
2026-05-04 - Framework links post-viral fatigue to stress erythropoiesis and hormonal drops
- What changed: A molecular framework based on blood transcriptomics and metabolomics identified that post-viral fatigue is driven by an expansion of immunosuppressive CD71+ erythroid precursors (“stress erythropoiesis”) and low cortisol and sex steroid levels.
- Why it matters: This shifts the paradigm to physiological recovery failure, explaining why standard hemoglobin tests miss stress erythropoiesis and pointing to hormone replacement as a targeted treatment direction.
- What it does not prove yet: The causal sequencing of stress erythropoiesis versus endocrine failure is not established, and hormone-based interventions require clinical trials.
Sources:
2026-05-07 - Sex-stratified metabolomics suggests arginine-NO dysregulation in male ME/CFS patients
At the International ME/CFS Conference 2026 in Berlin, Cornelia Pipper-Krampl presented a sex-stratified metabolomic analysis from the UK ME/CFS Biobank focused on arginine- and polyamine-related metabolites. The male ME/CFS subgroup showed increased arginine, homoarginine, and spermidine with reduced citrulline, while the female subgroup did not show significant differences in this targeted analysis. This pattern is consistent with altered arginine handling away from nitric oxide production and toward polyamine metabolism, which could matter for both vascular regulation and cellular energy stress. The finding is useful because it points to biological heterogeneity inside the ME/CFS label rather than assuming a single uniform metabolic signature. It does not yet show whether the apparent male-specific signal reflects a true sex difference, a power issue in the female subgroup, or a broader subgroup effect that needs replication.
Sources:
2026-05-07 - Brain phosphorus-MRS links reduced ATP-to-phosphocreatine ratios to cognitive impairment in post-COVID illness
Also presented at the International ME/CFS Conference 2026, Gabriele Ende reported whole-brain phosphorus-MRS findings in 27 people with Post-COVID Syndrome and 23 recovered controls, including 11 participants who also met Canadian Consensus Criteria for ME/CFS. The study found reduced ATP-to-phosphocreatine ratios in the cingulate region, and those lower ratios tracked with worse performance on cognitive testing. Functional MRI from the same project showed overlap between the low-energy region and failed anterior cingulate deactivation during a working-memory task, which strengthens the case that the signal reflects a functionally relevant energy-buffering problem rather than an incidental imaging difference. This is important because it moves the metabolic model into direct in vivo brain measurements. It remains an early conference-stage result from a single center using specialized equipment that is not yet widely available.
Sources:
2026-05-12 - Extracellular vesicles show shared immune cell mitochondrial alterations in patients
- What changed: A clinical study analyzing plasma extracellular vesicles (EVs) in 125 individuals showed elevated concentrations of leukocyte, macrophage, and platelet EVs, reduced B-cell EVs, and increased mitochondrial membrane potential in specific EV subsets.
- Why it matters: This provides blood-based evidence of shared immune-metabolic signaling disturbances in ME/CFS and Long COVID (ME/CFS phenotype), suggesting that vesicular mitochondrial potential is a promising biomarker.
- What it does not prove yet: The cross-sectional design cannot establish whether these vesicle alterations cause the disease or are secondary byproducts, and the study did not measure total mitochondrial mass to normalize the membrane potential signal.
Sources:
2026-06-10 - Dried blood spot metabolomics shows pathway-level convergence with ME/CFS biology in a large community cohort
Hauguel and colleagues profiled dried blood spot samples from 1,784 adults and tested whether a literature-guided metabolite panel could identify a self-reported PEM-like fatigue phenotype. A 22-metabolite panel reached an out-of-fold AUC of 0.81 and mapped back to pathways already familiar in ME/CFS work, including the carnitine shuttle, TCA cycle, redox-thiol balance, urea cycle, glycerophospholipids, and tryptophan-kynurenine metabolism. The main value here is not that it proves a diagnostic test, but that it shows a decentralized sampling method can still recover pathway-level signals similar to venous blood studies. The metabolomic score also rose with symptom severity, which supports biological gradient rather than a random assay artifact. The limitations are substantial: the phenotype was self-reported rather than clinically adjudicated, subgroup analyses were small, and untargeted screening in the same dataset mostly surfaced technical and environmental noise.
Sources:
2026-06-12 - Longitudinal handgrip study shows persistent objective muscle dysfunction in post-COVID illness
A prospective cohort study followed 102 people with Post-COVID Syndrome and 102 recovered controls, with 61.4% of the patient group meeting ME/CFS criteria. Patients had lower mean grip force, greater fatigability, and worse recovery capacity than controls at baseline and again 6 months later, with only modest improvement in recovery metrics over time. Lower baseline force and higher fatigability also predicted worse later symptom burden, which makes the result more clinically relevant than a one-time cross-sectional performance measure. This supports the idea that peripheral energy failure and muscle dysfunction remain objectively measurable over time in a large subset of post-viral patients. It still cannot show whether the muscle impairment is driven primarily by mitochondrial dysfunction, vascular perfusion problems, altered activity patterns, or some combination of these.
Sources:
2026-06-16 - Patient-derived myogenic cells show transcriptomic downshifts in muscle and energy pathways
Nguyen and colleagues generated induced pluripotent stem cell-derived myogenic progenitor cells from 6 female ME/CFS patients and 7 female controls, then performed RNA sequencing and in silico drug repurposing. Most differentially expressed pathways were downregulated, including cell-cycle, DNA-repair, immune, and muscle cytoskeleton programs, while upregulated pathways suggested greater reliance on branched-chain amino acid degradation for energy. That pattern fits the broader idea that muscle cells are adapting to chronic energetic stress rather than functioning normally at baseline. The authors also mapped 22 candidate repurposing drugs, but those outputs remain exploratory because the study did not test whether the compounds actually improve cell function. This is a useful mechanistic addition, but it is still a small female-only preprint based on an in vitro cell model rather than a whole-body human physiology study.
Sources:
Open Questions
- What is the primary cellular initiator of the acquired tissue hypoperfusion that leads to skeletal muscle mitochondrial damage and calcium-sodium overload?
- If circulating blood factors are not universal drivers of myoblast mitochondrial respiration defects, what localized or tissue-resident immune signals trigger cellular energy stress in patients?
- Does B-cell lipid accumulation and PTDSS1 enzyme hyperactivity directly contribute to B-cell dysfunction or autoimmune antibody production?
- Can therapeutic stabilization of mitochondrial membrane potential in extracellular vesicles prevent systemic neuroinflammatory signaling?
- To what extent can the clinical symptoms of post-exertional malaise be mitigated by targeting the WASF3-mediated ER stress response?